Abstract 495P
Background
Many preclinical studies have demonstrated the stimulative effect of STING agonists in immunotherapy, but their adverse effects prevent practical use. Previous research by our team found that STING has a more significant anti-tumor role in host immune cells than tumor cells, and the level of STING mRNA is related to the outcome of immunotherapy in non-small cell lung cancer. Although STING is necessary for CD8+T cells to exert immunological activity, its effect on CD8+T cells is debatable. Therefore, we will concentrate on the particular roles of STING in CD8+T cells.
Methods
We used in vitro and in vivo models to confirm the influence of STING on CD8+T cell function. We examined the impact of STING on CD8+T cell metabolic function using RNA-seq, seahorse, flow, electron microscopy, and other techniques. STING knockout mice were used to study the effect of competitive inhibition of glycolytic products during immunotherapy.
Results
RNA-seq showed significant changes in signaling pathways such as glycolysis/glycogen synthesis, oxidative phosphorylation, tricarboxylic acid cycle, and one carbon unit in STING-/- CD8+T cells. In vitro experiments revealed that the inactivation of the STING gene reduced the number of mitochondria, altered the choice of metabolic pathways, and impaired the anti-tumor ability. Flow results showed that the mean fluorescence intensity of mitochondria in STING-/- CD8+T decreased. Seahorse experiment showed that STING-/- CD8+T glycolysis was enhanced, and oxidative phosphorylation was decreased. Meanwhile, the content of lactic acid in the culture supernatant of STING-/- CD8+T increased dramatically, the high level of lactic acid further inhibited the proliferation of CD8+T and the secretion of IFN-γ. Competitive inhibition of the glycolysis process or lactic acid formation can save the function of STING-/- CD8+T cells and the secretion of IFN-γ, save the immunotherapy effect of STING-/- mice. This provides a new therapeutic idea for patients with low STING expression and poor immunotherapy response.
Conclusions
Our study is the first to explore the effect of STING on the metabolic process in CD8+ T cells. Intervening in the metabolic process of STING-deficient CD8+ T can save the efficacy of immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Provincial Social Development - General Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract